

CANN
GROUP LIMITED



Annual General Meeting

29 November 2019

Chairman's address

Allan McCallum

Refer to ASX Announcement lodged 29 November 2019

CEO's address

Peter Crock

Refer to ASX Announcement lodged 29 November 2019

Fully integrated & globally competitive medicinal cannabis company

- Cann is combining in-house capabilities with strategic partnerships to undertake
 - **Industry-leading research & product development**
 - **Cost-efficient cultivation on a large scale**
 - **Manufacturing of GMP grade medicinal products**
 - **Sales & marketing** to meet both Australian demand & valuable export opportunities
- Objective to provide all Australian patients with reliable, locally produced, GMP verified medicinal cannabis products. Cann's aim is to secure & maintain a leadership position across the entire medicinal cannabis value chain & be successful on a global scale



Key building blocks in place

- **Cultivars** – International genetics program has allowed Cann to test, identify & focus on strains with the most compelling attributes for cultivation at scale, including profiling strains required by Aurora
- **Licenses & Permits** – Holds all required licences & permits for cultivation, production, manufacturing, import & export
- **Track-Record** – 51 successful harvests in existing facilities
- **At-Scale Facility** – Construction of large scale facility to be developed on staged basis, with stage 1 commissioning targeted to start by late CY2020*
- **Domestic Distribution** – National wholesale & distribution agreement with Symbion to deliver Cann finished product through pharmacies & hospitals across Australia
- **Aurora Offtake** – Five year offtake agreement with Aurora for product in excess of Australian requirements
- **Global market development** – Ongoing development of marketing & supply opportunities in other overseas markets
- **Products** – Expanding range of locally produced & imported products ready for Australian patients
- **Team** – Experienced Board, management team & value-adding partnerships

⁵ * Subject to completion of detailed design & construction review, funding & necessary approvals

Large scale Mildura facility to be completed on staged basis

- State-of-the-art facility, incorporating world-leading design/technology
- Revised construction plan more closely aligns capacity with anticipated demand & lowers capital investment risk
- Detailed design; scheduling; & cost now being determined, with preliminary target to develop initial stage with up to 25,000kgs in capacity & commissioning to start by late CY2020*
- Timetable for stages 2 & 3 to be determined based on ongoing analysis of product demand
- Mildura expenditure to date – ~\$47m
 - Site acquisition & preparation
 - Repurposing of original buildings
 - Glasshouse structure erected
 - Glass installed



Image of Mildura facility – construction well underway







Proven cultivation & production model

- Ongoing cultivation & harvest cycle utilising Southern & Northern facilities
- 51 harvests completed including Aurora sourced cultivars
- 24 imported varieties of medicinal cannabis currently being evaluated
- First harvests of internationally sourced genetics completed
- Production from Southern facility servicing domestic supply initiatives & testing of export pathways
- Production from Northern facility supporting several research programs including La Trobe University ARC Medicinal Agriculture Research Hub & the NSW DPI CRCp research program – Cann is the lead commercial partner for both



Experienced pharmaceutical partner with product validation underway

- IDT Australia (ASX:IDT) for manufacturing support in relation to cannabis-based product formulations
- IDT brings excellent capabilities & experience in the manufacture of cGMP quality pharmaceuticals
- Partnership with IDT provides Cann an integrated pathway through the full supply chain
- Supercritical CO₂ extraction equipment, owned by Cann, installed & currently undergoing commissioning for full GMP compliance
- Production validation program underway



Existing pharmaceutical equipment at IDT Australia

Both local & imported products ready to launch

- Product development & validation on track for domestic launch of locally made Cann products by Q1 CY2020
- New imported product from Aurora received with first orders secured
- Wholesale & distribution agreement with Symbion (4,000 pharmacies, 1,300 hospitals nationally) to carry Cann's full range of imported & locally manufactured products within Australia



Regulatory approvals

- Manufacturing licences received for Cann's Southern & Northern facilities
- Cann holds all necessary cultivation, production & manufacturing licences in addition to import & export licences
- May 2019 – IDT Australia granted manufacturing licence
- June 2019 – Aurora receives import permit from Health Canada for cannabis cultivated by Cann
- Mildura licence in process



Strong relationship with Aurora Cannabis Inc


- Offtake agreement secured with Aurora for Cann's TGA/GMP quality product. Aurora has an established presence in 24 countries
- Agronomic support & access to cultivation & manufacturing related IP
- Technical Services Agreement between Cann & Aurora – provides for exchange of key information & support across cultivation, processing, extraction, manufacturing & analysis
- Aurora's leading global greenhouse design firm Aurora Larssen Projects engaged for Cann's Mildura facility



A growing domestic & export market

Australian patient approvals continue momentum

SAS Category B approvals by month



Source: Therapeutic Goods Administration / Australian Pharmaceutical Publishing


Export potential growing across worldwide

Medicinal cannabis market size forecast

Region	Market Value 2024 (US\$b)
Africa	1.3
Asia	10.7
Europe	22.3
Latam	6.6
North America	20.2
Oceania	1.5
Total	62.6

Source: Prohibition Partners

Clinical trials involving cannabis – 2019



Source: US National Library of Medicine/ Prohibition Partners

ITEM 1

Financial statements and reports

ITEM 2

Adoption of Remuneration Report

For	Proxy's Discretion	Against	Abstain
38,243,153	2,556,257	900,103	176,576

ITEM 3

Re-election of Director – Mr Allan McCallum

For	Proxy's Discretion	Against	Abstain
44,985,890	2,234,764	76,971	158,464

ITEM 4

Re-election of Director – Mr Douglas Rathbone

For	Proxy's Discretion	Against	Abstain
44,983,086	2,234,263	81,125	157,615

ITEM 5

Ratification of prior issue of shares

For	Proxy's Discretion	Against	Abstain
44,237,776	2,555,484	521,761	141,068

ITEM 6

Ratification of prior issue of shares

For	Proxy's Discretion	Against	Abstain
43,912,437	2,717,816	517,348	149,786

ITEM 7

Approval of long-term incentive plan

For	Proxy's Discretion	Against	Abstain
38,304,817	2,390,207	887,606	134,757

ITEM 8

Approval of 10% placement capacity for 12 months

For	Proxy's Discretion	Against	Abstain
43,730,163	2,404,488	1,172,905	148,533

CONTACTS:

Clive Fanning
Head of Investor Relations
Cann Group Limited
+61 (0)498 000 762
contact@canngrouplimited.com

Matthew Wright
Investor / Media Relations
NWR Communications
+61 (0)451 896 420
matt@nwrcommunications.com.au

